Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

12 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA sequencing of mouse haemopoietic cells 2014 15

ABSTRACT: Comprehensive analysis of AML genomes has revealed co-occurring mutations in DNA andhistone modifying enzymes suggesting their crucial role in tumourigenesis. To gain inside intothe role of those genes in AML we generated mouse models recapitulating mutations in partof the most frequent ones. We hypothesise that aberrant chromatin modification andunderlying effect on gene expression largely contribute to leukemogenesis. To test thishypothesis we propose to compare gene expression and DNA and histone modification in thepresence or absence of single gene mutation in mouse hematopoietic stem and progenitorcompartment in a pre-leukaemia setting. Characterisation of these models will inform thebiology of AML, identify potential therapeutic targets and provide platforms for theassessment of novel therapeutics.This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/

INSTRUMENT(S): Illumina HiSeq 2500

ORGANISM(S): Mus musculus

SUBMITTER:

PROVIDER: E-ERAD-322 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Acquisition of additional mutations drives accelerated progression of NPM1 positive mice to AML Part II

Project description:We performed exome sequencing on samples from mice with accute myeloid leukeamia (AML). These mice were already sensitised to developing AML by the presence of mutations known to be key in the AML genesis. Exome sequencing was used to identify co-operating mutations in single and double mutant sensitised mice. Here we are performing re-sequencing of the putative driver and some passenger mutations which appear to be in the same clone to validate these mutations and to verify the relative quantification of these abnormalities .This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/

2015-09-08 | E-ERAD-393 | biostudies-arrayexpress

RNA sequencing of mouse haemopoietic cells

Project description:This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/

2014-09-02 | E-ERAD-290 | biostudies-arrayexpress

RNA sequencing of mouse haemopoietic cells

2014-11-11 | E-ERAD-295 | biostudies-arrayexpress

CRISPR Cas9 screens for drug resistance in AML cell lines

Project description:Acute myeloid leukaemia (AML) continues to have a very high mortality and its treatment hasnot changed for more than 20 years.Here, we propose to apply genomic-wide screens to directly identify therapeutic vulnerabilitiesof AML using AML cells lines with pre-defined somatic mutations. Our studies will be basedon genome-wide CRISPR/CAs9 gRNA screens and will be used to identify drivers of drugresistance to standard chemotherapies.This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/

2015-02-03 | E-ERAD-335 | biostudies-arrayexpress

FLT3 Insertional Mutagenesis Mapping in AML

Project description:FLT3 is a key driving mutation in AML leukaemogenesis. RNASeq will be used to identify & validate cooperating mutations in a number of FLT3 IM mouse samples This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/

2016-04-12 | E-ERAD-435 | biostudies-arrayexpress

RNA sequencing of mouse haemopoietic cells BCMX ASMX SMMX HNMX DPMX DTMX

2014-10-06 | E-ERAD-304 | biostudies-arrayexpress

CLASH RNAseq of RNP bound RNAs

Project description:We are investigating the possible role of ribonucleoprotein-bound RNAs on the pathogenesis of AML. This study uses antibody-pulldown of specific ribonucleoproteins followed by RANSeq. We hope to describe this interaction in wild type cells befire studying the effects of specific mutations This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/

2014-03-25 | E-ERAD-226 | biostudies-arrayexpress

Mouse melanoma cell lines transcriptome sequencing

Project description:n this project we have sequenced the transcriptome of several comonly used mouse melanoma cell lines. Our aim is to understand what mutations and rearrangements are found in these cell lines to gain a better understanding of the genes that contribute to melanomagenesis. As these cell lines are used as models of melanoma these sequences represent an important resource for functional studies. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/

2015-01-17 | E-ERAD-94 | biostudies-arrayexpress

Alkynyl nicotinamides with antileukemic activity to treat poor prognosis AM

Project description:FLT3 activating mutations cause myeloproliferative neoplasms by deregulating hematopoietic progenitor cell growth, and acute myeloid leukemia is on the rise. Investigational drugs targeting mutant FLT3, including Quizartinib and Crenolanib, develop inherent and acquired resistance to FLT3 targeted therapy. FLT3 inhibitor resistance in AML is dependent on co-occurring mutations, parallel survival pathways, and/or subsequent FLT3-ITD mutations. Despite the high prevalence of FLT3 mutations and their clinical significance in AML, there are few targeted therapeutic options. We identified two novel naphthyridine-based FLT3 inhibitors (HSN608 and HSN748) that specifically target FLT3-ITD at sub-nanomolar concentrations and are effective against drug-resistant secondary mutations. In the current study, we evaluated these compounds antileukemic activity against FLT3-ITD and gatekeeper mutations in drug-resistant AML, relapsed/refractory AMLs with FLT3 mutations, and in vivo mouse models with combinations of epigenetic mutations TET2 with FLT3-ITD, and AML patients PDX. In these model systems, we demonstrate that HSN748 outperforms the FDA-approved FLT3 inhibitor Gilteritinib in terms of inhibitory activity against FLT3-ITD.

2022-12-07 | MSV000090855 | MassIVE

Project description:AML mouse models

| PRJNA144117 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data